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OBJECTIVE—At least 20 type 2 diabetes loci have now been
identiﬁed, and several of these are associated with altered -cell
function. In this study, we have investigated the combined effects
of eight known -cell loci on insulin secretion stimulated by
three different secretagogues during hyperglycemic clamps.
RESEARCH DESIGN AND METHODS—A total of 447 sub-
jects originating from four independent studies in the Nether-
lands and Germany (256 with normal glucose tolerance [NGT]/
191 with impaired glucose tolerance [IGT]) underwent a
hyperglycemic clamp. A subset had an extended clamp with
additional glucagon-like peptide (GLP)-1 and arginine (n  224).
We next genotyped single nucleotide polymorphisms in TCF7L2,
KCNJ11, CDKAL1, IGF2BP2, HHEX/IDE, CDKN2A/B, SLC30A8,
and MTNR1B and calculated a risk allele score by risk allele
counting.
RESULTS—The risk allele score was associated with lower
ﬁrst-phase glucose-stimulated insulin secretion (GSIS) (P 
7.1  10
6). The effect size was equal in subjects with NGT and
IGT. We also noted an inverse correlation with the disposition
index (P  1.6  10
3). When we stratiﬁed the study population
according to the number of risk alleles into three groups, those
with a medium- or high-risk allele score had 9 and 23% lower
ﬁrst-phase GSIS. Second-phase GSIS, insulin sensitivity index
and GLP-1, or arginine-stimulated insulin release were not sig-
niﬁcantly different.
CONCLUSIONS—A combined risk allele score for eight known
-cell genes is associated with the rapid ﬁrst-phase GSIS and the
disposition index. The slower second-phase GSIS, GLP-1, and
arginine-stimulated insulin secretion are not associated, suggest-
ing that especially processes involved in rapid granule recruit-
ment and exocytosis are affected in the majority of risk loci.
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T
ype 2 diabetes is a polygenic disease in which
the contribution of a number of detrimental gene
variants in combination with environmental fac-
tors is thought to be necessary for the develop-
ment of disease. In the past 2 years, results of several
genome-wide association studies (GWASs) have been pub-
lished (1–5), leading to a rapidly increasing number of
detrimental type 2 diabetes susceptibility loci. More re-
cently, it has indeed been shown that combining informa-
tion from these diabetes loci into a risk allele score for all
loci enhances diabetes risk (6–9). However, the predictive
power of this combined risk allele score is yet insufﬁcient
to substitute or largely improve predictive power of
known clinical risk factors (8,9). At present, little is known
about how these gene variants in combination affect
insulin secretion or insulin resistance. Based on recent
data, mainly obtained from oral glucose tolerance tests
(OGTTs), it was shown that a combined risk allele score
from gene variants associated with type 2 diabetes is
associated with insulin secretion and not with insulin
sensitivity (10–13). However, the OGTT is unable to
distinguish between ﬁrst- and second-phase insulin secre-
tion. Furthermore, other secretagogues, like glucagon-like
peptide (GLP)-1 and arginine, were not included in these
studies.
It is thought that the rapid recruitment and release of
insulin granules from the readily releasable pool (RRP) is
responsible for the ﬁrst phase of insulin secretion,
whereas the slower prolonged second phase involves
recruitment to the membrane of more distant granules and
de novo insulin synthesis. Although the exact pathways
regulating both phases of glucose-stimulated insulin secre-
tion (GSIS) are not completely resolved, it seems logical
that they are at least in part different. This is further
corroborated by our recent observation that the heritabil-
ity for both phases of GSIS in twins is derived from partly
nonoverlapping sets of genes (13a).
Also, other nonglucose, stimuli-like incretins and amino
acids can evoke an insulin response. Detailed phenotypic
investigations of the response to these different stimuli
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affected by these loci. Previously, we have already shown
that type 2 diabetes genes/loci can have different effects on
ﬁrst- and second-phase GSIS, as measured using hypergly-
cemic clamps. Also, based on the method of stimulation
(i.e., oral versus intravenous), the outcome may differ
substantially (14–17), which provides further clues about
the mechanism by which they affect insulin secretion.
In this study, we genotyped gene variants in TCF7L2,
KCNJ11, HHEX/IDE, CDKAL1, IGF2BP2, SLC30A8,
CDKN2A/CDKN2B, and MTNR1B in 447 hyperglycemic
clamped subjects (256 with normal glucose tolerance
[NGT] and 191 with impaired glucose tolerance [IGT])
from four independent studies in the Netherlands and
Germany. These eight loci were chosen based on the fact
that they were reproducibly associated with -cell func-
tion in various studies (rev. in 18,19). A combined risk
allele score of all eight gene variants was calculated for
each individual and tested against the various detailed
measurements of -cell function using the hyperglycemic
clamp, generally considered to be the gold standard for
quantiﬁcation of ﬁrst- and second-phase GSIS (20). Fur-
thermore, we also assessed the combined effect of these
eight genes on two other stimuli, GLP-1 and arginine-
stimulated insulin secretion during hyperglycemia, in a
subset of the study sample (n  224). The latter test
provides an estimation of the maximal insulin secretion
capacity of a subject and may, according to animal studies,
serve as a proxy for -cell mass (21).
RESEARCH DESIGN AND METHODS
Hyperglycemic clamp cohorts. Four independent studies from the Nether-
lands (NL) and Germany (D) were used. The clinical characteristics of the
study groups are given in Table 1. Details of three of four samples have
previously been described (Hoorn [NL, 137 with IGT]; Utrecht [NL, 60 with
NGT/12 with IGT]; Tu ¨bingen [D, 83 with NGT/35 with IGT]) (17). We have
extended our study sample with a cohort selected from the Netherlands Twin
Register (NTR; 113 with NGT/7 with IGT) (22). This cohort consists of a mixed
sample of twins and nontwin sibs recruited from 50 families (family size 1–9).
In total, the NTR twin sample includes 66 monozygotic twins (31 pairs), 25
dizygotic twins (11 pairs), and 29 nontwin sibs (14 twin, nontwin sib pairs; 1
single nontwin sib).
Hyperglycemic clamp procedure. All participants underwent a hyperglyce-
mic clamp at 10 mmol/l glucose for at least 2 h (21,23–26). After a priming
infusion of glucose to acutely raise blood glucose levels, blood glucose levels
were measured with a glucose analyzer and kept constant at 10 mmol/l during
the whole clamp. Insulin levels were measured with immunoassays as
previously described (21,23–26). To correct for this and possible other
differences between centers, we introduced a dummy variable (study center)
in our statistical analyses. First-phase insulin secretion was determined as the
sum of the insulin levels during the ﬁrst 10 min of the clamp. Second-phase
insulin secretion was determined as the mean of the insulin levels during the
last 40 min of the second hour of the clamp (80–120 min). The insulin
sensitivity index (ISI) was calculated by relating the glucose infusion rate (M)
to the plasma insulin concentration (I) during the last 40 min of the second
hour of the clamp (M/I). Mitrakou et al. (27) compared the ISI determined with
a hyperglycemic clamp with insulin sensitivity as determined using the
euglycemic-hyperinsulinemic clamp in the same subjects and found a good
agreement between the two methods. The disposition index (DI) was calcu-
lated by multiplication of ﬁrst-phase insulin secretion and ISI in order to
quantify insulin secretion in relation to the ambient insulin sensitivity (28,29).
Subjects from Tu ¨bingen and the NTR twin sample both underwent an
extended clamp using additional GLP-1 and arginine stimulation as described
previously (21). GLP-1–stimulated insulin release was measured as the mean
incremental area under the curve (160–180 min) following GLP-1 stimulation
(4.5 pmol/kg bolus for 1 min at t  120 followed by a continuous infusion of
1.5 pmol  kg
1  min
1. In the Dutch NTR twin cohort, slightly lower GLP-1
concentrations were used (1.5 pmol/kg and 0.5 pmol  kg
1  min
1, respec-
tively). Arginine-stimulated acute insulin release was measured by injecting a
bolus of 5 g arginine hydrochloride at t  180 as described previously (21).
The acute insulin response to arginine was calculated as the mean incremental
area under the curve from 182 to 185 min.
Genotyping. Based on the available literature regarding GSIS and the novel
type 2 diabetes genes, we selected gene variants in TCF7L2 (rs7903146),
KCNJ11 (rs5219), CDKAL1 (rs7754840), IGF2BP2 (rs4402960), HHEX/IDE
(rs1111875), SLC30A8 (rs13266634), CDKN2A/B (rs10811661), and MTNR1B
(rs10830963) for genotyping. Results of the association analysis of the effect of
the individual genes on GSIS during hyperglycemic clamps in the Dutch Hoorn
and Utrecht study and the German Tu ¨bingen study have been published
previously (14–17).  and P values for all four samples combined, including
the Dutch NTR twins, are given in supplementary Table 1 (available in the
online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0736/DC1). All single nucleotide polymorphisms (SNPs) were measured
using either the Sequenom platform (Sequenom, San Diego, CA) or Taqman
SNP genotyping assays (Applied Biosystems, Foster City, CA) in all subjects.
The genotyping success rate was 97% for all SNPs, and samples measured in
duplicate (5%) revealed no errors.
Statistics. We combined the information of the SNPs using an allele count
model (6). We summed the number of risk alleles carried by each individual,
assuming an equal and additive effect of each allele. The effect of the sum
score of risk alleles on the responses was examined by calculating the 
values for the risk allele score with linear generalized estimating equations,
which takes into account the family relatedness when computing the standard
errors (i.e., in the twin sample). For ease of interpretation, the exponent 
values (10
) are given throughout the article. For analyses of ﬁrst- and
second-phase GSIS, GLP-1 and arginine-stimulated insulin secretion adjust-
ment for age, sex, BMI, study center, glucose tolerance status, and ISI were
used. For the analysis of ISI and DI, ISI was removed from the model. All
outcome variables were log-transformed prior to analysis. Logistic regression
with adjustment for age, sex, and BMI was used to test associations with
dichotomous end points like the absence of a ﬁrst-phase insulin peak and type
2 diabetes. A priori power calculations showed that the design used in this
study would allow the detection of a difference in insulin secretion between
10% (glucose) to 25% (GLP-1, arginine) with 80% power (0.05), depending
on the stimulus used and allele frequency. All data are given as estimated
mean (95% CI) unless otherwise stated. After correction for multiple hypoth-
esis testing, results were regarded signiﬁcant at P  0.008 (six tests). For all
statistical analyses, SPSS version 16.0 software (SPSS, Chicago, IL) was used.
RESULTS
The risk allele counts for the eight -cell genes were
normally distributed in our participants (supplementary
TABLE 1
Clinical characteristics of the hyperglycemic clamp cohorts
The Netherlands Germany
(Tübingen)* Hoorn* Utrecht* NTR twins*
n (NGT/IGT) 137 (0/137) 72 (60/12) 120 (113/7) 118 (83/35)
Sex (M/F) 64/73 17/55 55/65 51/67
Age (years) 60.5 	 8.7 46.6 	 6.7 31.6 	 6.4 39.2 	 13.2
BMI (kg/m
2) 28.0 	 4.0 25.9 	 3.8 24.1 	 3.5 25.5 	 5.4
Fasting plasma glucose (mmol/l) 6.3 	 0.7 4.7 	 0.5 4.6 	 0.4 5.1 	 0.7
2-h plasma glucose (mmol/l) 8.8 	 1.7 5.7 	 1.6 5.4 	 1.2 6.5 	 2.0
Fasting plasma insulin (pmol/l) 62 (46–91) 36 (24–54) 40 (26–47) 43 (30–66)
Data are means 	 SD or medians (interquartile range). *Original population from which the cohort originated (21–26).
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tween the number of risk alleles and ﬁrst-phase GSIS (
0.95 [95% CI 0.93–0.97]; P  7.1  10
6) (Fig. 1), indicating
that ﬁrst-phase GSIS decreases with a factor of 0.95 with
each additional risk allele. The observed effect size on
ﬁrst-phase GSIS was equal in both subjects with NGT and
IGT (NGT  0.95, P  4.6  10
5, and IGT  0.95, P 
0.015, respectively). Furthermore, the effect was present in
each of the separate study samples ( range 0.93–0.96, all
P  0.08). There was no signiﬁcant effect of the number of
risk alleles on second-phase GSIS or ISI (both P  0.13).
However, there was also an inverse correlation with the DI as
measured by the clamp (0.96 [95% CI 0.94–0.99]; P 
1.6  10
3). The risk allele score explains 4% of the variance
in ﬁrst-phase GSIS and 5% of the variance in the DI.
To examine whether our results can be attributed to the
effect of one or more single loci, we also added the single
loci to the model with the risk allele score; however, none
of the single loci remained signiﬁcant in this analysis (all
P  0.3). Previously, we showed that three single loci are
signiﬁcantly associated with ﬁrst-phase GSIS (CDKAL1,
IGF2BP2, and MTNR1B) (supplementary Table 1) (14–
17,30). Therefore, we also tested a model that includes the
three signiﬁcant single loci and a combined risk allele
score for the remaining ﬁve loci (TCF7L2, KCNJ11,
HHEX, SLC30A8, and CDKN2A/B). In this analysis, the
ﬁve-gene risk allele score still added signiﬁcant informa-
tion to the model (P  0.05).
For ease of interpretation, we next stratiﬁed the partic-
ipants into three approximately equally sized strata; carri-
ers of a low (less than seven risk alleles, n  141, 32%),
medium (7–8 risk alleles, n  183, 40%), and high number
of risk alleles (more than eight risk alleles, n  123, 28%).
The characteristics of the three groups are given in Table
2 and the results per study sample in supplementary Table
2. Analysis of the difference in ﬁrst-phase GSIS between
these different strata showed a 9 and 23% lower ﬁrst GSIS
in the medium and high strata compared with the refer-
ence group (low) (Ptrend  5.9  10
6) (Fig. 2). Analysis
of the differences in DI between these groups showed a 9
and 17% reduction in DI (Ptrend  2.9  10
3) (Table 2).
Again, no signiﬁcant difference between the strata was
FIG. 1. First-phase GSIS in relation to the risk allele counts for the
eight loci. Each circle represents an independent participant. The line
represents the regression line after adjustment for age, sex, BMI, study
center, glucose tolerance status, and ISI. 0.95 (95% CI 0.93–0.97);
P  7.1  10
6.
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not observe an association of the number of risk alleles and
GLP-1–stimulated insulin release during the clamp (Table 2).
Furthermore, the maximal insulin secretion capacity as mea-
sured by arginine stimulation was not affected by the number
of risk alleles present (P  0.65) (Table 2).
Recently, we have shown that a four-gene risk allele
score alters the age-related decline in -cell function in
obese subjects as measured by OGTT (11). Although we
have a limited number of obese subjects in the present
study (BMI 30 kg/m
2, n  66), we noted a similar
increased decline in -cell function in obese subjects with
a higher number of risk alleles (ﬁrst-phase GSIS: low 
1.01 [95% CI 0.99–1.03], P  0.46; medium  0.98 [0.96–
0.99], P  1.1  10
3; high  0.97 [0.96–0.99], P  5.5 
10
3).
Previously, we have shown that the absence of a ﬁrst-
phase insulin peak is a strong predictor of future develop-
ment of type 2 diabetes in subjects with IGT (26). In the
present study, subjects with IGT without a ﬁrst-phase peak
had on average 1.28 (95% CI 0.71–1.85) more risk alleles
than those with a peak (P  1.0  10
5). In three strata,
the frequency of an absent ﬁrst-phase peak increased from
12% in the low group to 40% in the high stratum (Ptrend 
6.9  10
4, adjusted for age, sex, and BMI) (Table 3).
Those with a medium or high number of risk alleles also
had an increased risk of conversion to type 2 diabetes
during follow-up; however, due to the small numbers, this
was not signiﬁcant (Table 3).
DISCUSSION
In this study, we have shown that a risk allele score for
eight -cell loci is associated with lower glucose-stimu-
lated ﬁrst-phase insulin secretion but not with other
measures of -cell function. Previously, three other groups
investigated the relationship between a risk allele score of
-cell loci and GSIS. Pascoe et al. (10) used a risk allele
score of seven loci (TCF7L2, KCNJ11, HHEX/IDE, CDKAL1,
IGF2BP2, SLC30A8, and CDKN2A/B), whereas Haupt and
colleagues (10–12) used four loci for his main analyses
(TCF7L2, CDKAL1, HHEX/IDE, and SLC30A8). Finally,
Stanc ˇa ´kova ´ et al. (13) recently reported the results of a
risk allele score identical to the one used in this study. All
three groups mainly used data from OGTTs in nondiabetic
volunteers and were able to show that their risk allele
scores are inversely correlated with -cell function. The
novelty of our study is the fact that we used hyperglycemic
clamps with three different stimuli and the extended risk
allele score including eight proven -cell loci (TCF7L2,
KCNJ11, HHEX/IDE, CDKAL1, IGF2BP2, SLC30A8,
CDKN2A/B, and MTNR1B, a gene for which it has recently
been shown that it is associated with type 2 diabetes and
reduced GSIS) (30–33). We were able to show that only
the ﬁrst-phase GSIS is associated with our combined risk
allele score. In contrast, the other measures of -cell function
and insulin sensitivity were not associated. Furthermore, we
noted a signiﬁcant association with a lower DI (which is the
product of ﬁrst-phase GSIS  ISI), suggesting that the
investigated subjects are unable to compensate adequately
for a diminished insulin sensitivity (29). Previously, it has
been shown that a low DI is associated with glucose intoler-
ance and highly predictive for future diabetes (34). Remark-
ably, the alterations in ﬁrst-phase GSIS and DI are already
present in subjects with NGT, suggesting that these defects
are either present from birth on or develop well before the
onset of hyperglycemia. Interestingly, it appears from our
previous (11) and current data that environmental and/or
genetic factors acting on obesity interact with the genetic
effects on -cell function by altering the rate of the age-
related decline in -cell function.
Our data highlight the importance of using different
methods to investigate various aspects of insulin secre-
tion. Whereas previous studies have shown that these
genes together can affect overall insulin secretion during
OGTTs, this report reﬁnes this important observation by
showing that mainly the ﬁrst phase of GSIS is affected.
This suggests that their combined effect primarily involves
processes regulating the rapid recruitment and exocytosis
of insulin granules following glucose stimulation.
SLC30A8 encodes a -cell–speciﬁc Zn transporter impor-
tant for insulin storage, stability, and granule exocytosis,
which may ﬁt well with the observed defect (35). For the
other genes, it is less clear how they may affect the ﬁrst
phase of GSIS. However, for one of the genes present in
our risk allele score, TCF7L2, its role in insulin granule
recruitment and exocytosis was recently supported by
cell-based studies using overexpression or knock down of
the gene (36).
As we and others have shown previously, the genetic
variation in TCF7L2 mainly affects GLP-1–induced insulin
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FIG. 2. Mean estimated ﬁrst-phase GSIS in three different risk allele
strata. Those with three to six risk alleles were used as a reference
group.
TABLE 3
Impaired glucose-tolerant group details and follow-up
Group (number
of risk alleles) n
First-phase peak
absent/present
Type 2 diabetes
during follow-up
(n  93) (yes/no)
Low (6) 51 6/45 (0.12) 9/20 (0.31)
Medium (7–8) 75 21/54 (0.28) 14/24 (0.37)
High (9) 47 20/30 (0.40) 13/13 (0.50)
P 4.7  10
3 0.16
Pmodel 1 6.9  10
4 0.19
Stratiﬁcation according to the number of risk alleles in subjects with
IGT only. Absence of the ﬁrst-phase peak was deﬁned according to
the method of Nijpels et al (26). Numbers in parentheses are
percentages of total. P  unadjusted; Pmodel 1 is P value after logistic
regression analysis adjusted for age, sex, and BMI.
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GLP-1–induced insulin secretion with increasing number
of risk alleles could be detected. This may have several
reasons. First, this incretin resistance mediated by varia-
tion in TCF7L2 is likely to be masked in the present
analysis by the other seven risk loci that have no known
effect on incretin-induced insulin secretion. This also
suggests that the association of the risk allele score with
ﬁrst-phase GSIS is not dominated by the effects of a single
locus but rather reﬂects the addition of independent risk
mechanisms from all loci together. This is further corrob-
orated by the fact that when we tested for dominance of
single genes, by adding them to the model, there were no
associations with the single loci. Second, the power of the
present analysis may be too low considering the relatively
small subgroup in which we assessed the GLP-1–induced
insulin secretion (n  224).
Several of the loci present in our risk allele score are
putatively involved in transcriptional and/or cell cycle
control, and it has been suggested that they may cause a
reduced -cell mass leading to the observed -cell defects
(19,38,39). However, our data show that our risk allele
score of eight proven -cell genes is not associated with
arginine-induced insulin secretion during hyperglycemia, a
marker of (near) maximal insulin secretion capacity,
which has been proposed as a proxy for -cell mass (21).
The ﬁnding that a higher risk allele score has no effect
on second-phase GSIS, incretin-induced insulin secretion,
or maximal insulin secretion capacity in subjects with
NGT and IGT does not exclude a relevant role of these
mechanisms in the -cell defects leading to type 2 diabe-
tes. However, we may conclude that the reduced ﬁrst-
phase GSIS is the ﬁrst and prominent -cell defect leading
to type 2 diabetes. This is in accordance with our recent
ﬁnding that the absence of a ﬁrst-phase insulin peak during
hyperglycemic clamps was the best predictor of future
development of type 2 diabetes in subjects with IGT
(hazard ratio 5.74 [95% CI 2.60–12.67]) (26). The strong
correlation we observe between our risk allele score and
the absence of a ﬁrst-phase peak in our subjects with IGT
suggests that the eight genes we tested might be a better
predictor of future type 2 diabetes compared with the
generally used risk allele score of all known type 2
diabetes genes. However, due to the very small number of
converters in our study, this hypothesis should be tested in
larger, more suitable, prospective study samples.
One of the strong aspects of our studies is the fact that
we use four independent study samples from the Nether-
lands and Germany, which largely reduced the chance of
false-positive ﬁndings. However, although this is the larg-
est study sample available using hyperglycemic clamps to
test associations between diabetes loci and -cell func-
tion, we cannot exclude that we have missed some of the
more subtle alterations. Larger samples including type 2
diabetic subjects and perhaps other sophisticated tests of
-cell function would be needed to fully explore all
aspects of -cell function regarding these diabetes loci.
In conclusion, we show that a combined score of risk
alleles for eight -cell loci is associated with reduced ﬁrst-
but not second-phase GSIS or maximal insulin secretion
capacity. Furthermore, in subjects with IGT, there was a
strong correlation with the absence of a ﬁrst-phase insulin
peak, which is a strong predictor of future development of
type 2 diabetes. Our data provide evidence that the -cell
loci identiﬁed thus far act mainly via detrimental effects on
processes involved in the early, rapid recruitment and
exocytosis of insulin granules after glucose stimulation
rather than altering maximal insulin secretion capacity.
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